Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

4sU-seq of EV vs PRL3 expressing melanoma cells

ABSTRACT: 4sU-seq of EV vs PRL3 expressing melanoma cells

PROVIDER: PRJNA525649 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR8669690_1.fastq.gz	Fastqsanger.gz
	SRR8669690_2.fastq.gz	Fastqsanger.gz
	SRR8669700_1.fastq.gz	Fastqsanger.gz
	SRR8669700_2.fastq.gz	Fastqsanger.gz
	SRR8669710_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 72

Similar Datasets

4sU-seq of EV vs PRL3 expressing melanoma cells

Project description:We report the use of 4sU-seq to determine the role of PRL3 in transcriptional processivity in human melanoma cells overexpressing either PRL3 or empty vector control. Genome-wide analysis of read coverage across length of equalised genes revealed a distinct accumulation of transcripts towards the 5’ end in PRL3 overexpressing cells. Furthermore, we identify the genes that were enriched with 5’ transcripts in the PRL3 expressing cells by comparing the intronic read counts (normalized for length) at the 5’ and 3’ end of the gene and termed this metric the transcriptional processivity ratio (TPR). Comparing the TPRs for each gene between control cells and cells expressing PRL3, we found 1745 genes that were enriched for transcripts at the 5’ end and 40 genes that were enriched at the 3’ end in the PRL3 expressing melanoma cells compared with controls. Over 62% of the genes with altered TPRs showed a significantly altered change in total RNA differential expression analysis between PRL3 cells and control cells. These data illustrate a function for PRL3 in the regulation of transcriptional processivity that is enough to substantially alter steady-state mRNA levels.

2020-07-10 | GSE127855 | GEO

Secretome containing extracellular vesicles (EV) from cardiovascular progenitors (EV-CPC) vs the secretome containing EV from Fibroblasts (EV-FB)

Project description:Secretome containing extracellular vesicles (EV) seem to mediate the benefits of cell therapy for ischemic heart failure. Our project has the objective of comparing the secretome containing extracellular vesicles (EV) from cardiac progenitor cells (EV-CPC) vs the secretome containing EV from Fibroblasts (EV-FB) in order to stablish a protein cartography of EV-CPC and the biological pathways that they are involved. seem to mediate the benefits of cell therapy for ischemic heart failure. Our project has the objective of comparing the secretome containing extracellular vesicles (EV) from cardiac progenitor cells (EV-CPC) vs the secretome containing EV from Fibroblasts (EV-FB) in order to stablish a protein cartography of EV-CPC and the biological pathways that they are involved.

2023-09-22 | PXD022129 | Pride

CYGB+ expressing vs non cytoglobin expressing cells (NCE) (MOCK)

Project description:CYGB+ expressing vs non cytoglobin expressing cells (NCE) (MOCK)

| PRJNA540265 | ENA

1833 cells expressing RKIP vs control

Project description:1833 cells expressing RKIP vs control

| PRJNA205363 | ENA

Gene expression profile of HoxA9 over expressing and empty vector (EV) control Hemato-Endothelial Progenitors (HEPs) subpopulations

Project description:During hematopoietic differentiation of hESCs, HOXA9 expression parallels hematopoietic development but is restricted to the hemogenic precursors (HEP, CD31+CD34+CD45-), and diminishes as HEPs differentiate into blood cells (CD45+). Enforced expression of Hoxa9 in hESCs robustly promoted differentiation into primitive (CD34+CD45+) and total (CD45+) blood cells with higher clonogenic (CFU) potential. To identify patterns of gene expression that could explain at the molecular level the developmental impact of HOXA9 in hematopoietic commitment of hESCs, we performed gene expression profile in FACS-purified EV- and HOXA9-HEPs. 10^5 HoxA9 over expressing and EV control HEPs purified by FACS from H9 and AND1 hEBs at day 15 of hematopoietic differentiation were used for gene expression analysis using Whole Human Genome Oligo Microarray chips (Agilent Technologies).

2014-09-03 | E-GEOD-61017 | biostudies-arrayexpress

TAZ-CAMTA1 vs TAZ4A expressing MS1 cells

Project description:TAZ-CAMTA1 vs TAZ4A expressing MS1 cells

| PRJNA659043 | ENA

Expression data from second oncogene expressing Melanoma Cells.

Project description:Expression data from second oncogene expressing Melanoma Cells.

| PRJNA506456 | ENA

Transcriptome analysis of melanoma cells stably expressing BMP6

Project description:Transcriptome analysis of melanoma cells stably expressing BMP6

| PRJNA690945 | ENA

Effect of 4sU labeling concentrations on quantification bias in nucleotide conversion RNA-seq data

Project description:To investigate the effect of increasing 4sU labeling concentrations on quantification bias in nucleotide conversion RNA-seq, we labeled 3 different cell lines with increasing concentrations of 4sU. We then measured 4sU dropout in 4sU samples compared to 4sU naive samples.

2024-02-06 | GSE229504 | GEO

Melan-a mouse melanocytes vs. B16 mouse melanoma cells

Project description:Gene expression profile of melan-a mouse melanocytes vs. B16 mouse melanoma cells. Keywords: Cell type comparison

2008-07-31 | GSE11584 | GEO